C3 GLOMERULOPATHY (C3G)
Clinical trials for C3 GLOMERULOPATHY (C3G) explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY (C3G) trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY (C3G), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug CPV-104 enters first human trials for rare kidney disorder
Disease control Recruiting nowThis study tests a new medicine called CPV-104 for the first time in people. It is designed to calm an overactive part of the immune system that causes damage in C3 glomerulopathy (C3G), a rare kidney disease. The trial includes healthy adults and people with C3G to check safety,…
Matched conditions: C3 GLOMERULOPATHY (C3G)
Phase: PHASE1 • Sponsor: eleva GmbH • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New hope for rare blood and kidney diseases: early access to iptacopan
Disease control AVAILABLEThis program offers early access to the drug iptacopan for people with serious conditions like C3 glomerulopathy (a kidney disease) or paroxysmal nocturnal hemoglobinuria (a blood disorder) who have no other treatment options. Doctors can request the drug for patients who are not…
Matched conditions: C3 GLOMERULOPATHY (C3G)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:04 UTC